Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

REVEALED: Why is nektar therapeutics stock trading lower on thursday | Vintage Vibes

Nektar_Sign-San_Francisco-1

Editor’s Note: This article has been updated to correct an earlier inaccuracy regarding the company’s stock trajectory.

Nektar Therapeutics Inc. (NASDAQ:NKTR) on Thursday shared new data from its ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, at the 2025 European Academy of Dermatology and Venereology Congress.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.